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Abstract
Background: To investigate the association between myositis autoantibodies and clinical subsets of inflammatory
myositis in Korean patients.
Methods: Immunoprecipitation was performed using the sera of classic polymyositis (PM) (n = 11) and
dermatomyositis (DM) (n = 38) patients who met the Bohan and Peter criteria for definite inflammatory myositis. A
panel of defined myositis autoantibodies was surveyed to investigate the association between each autoantibody
and clinical subsets of inflammatory myositis.
Results: Either MSAs, anti-p140, or anti-p155/140 antibodies were found in 63.3% (31/49) of the study subjects.
Anti-140-kDa-polypeptide (anti-p140) (18.4%, 9/49) and anti-155/140-kDa polypeptide (anti-p155/140) (16.3%, 8/49)
antibodies were the most common, followed by anti-Mi2 (14.3%, 7/49), anti-ARS (12.2%, 6/49) and anti-SRP (2.0%,
1/49) antibodies. All MSAs and anti-p140 and anti-p155/140 antibodies were mutually exclusive. Anti-p140 (23.7%,
9/38), anti-p155/140 (21.1%, 8/38), and anti-Mi2 (18.4%, 3/38) antibodies were found exclusively in DM patients.
Anti-p140 antibody was associated with rapidly progressive interstitial lung disease (ILD) (p = 0.001), with a
sensitivity of 100.0% (4/4) and a specificity of 85.3% (29/34) in DM patients. Anti-p155/140 antibody was associated
with cancer-associated DM (p = 0.009), with a sensitivity of 55.6% (5/9) and a specificity of 89.7% (26/29). Cancer-
associated survival was significantly worse when anti-p155/140 antibody was present (19.2 ± 7.6 vs. 65.0 ± 3.5
months, p = 0.032). Finally, anti-ARS antibodies were associated with stable or slowly progressive ILD in PM and
DM patients (p = 0.005).
Conclusions: Anti-p140 and anti-p155/140 antibodies were commonly found autoantibodies in Korean patients
with inflammatory myositis. Despite the lack of clinically amyopathic DM patients in the study subjects, a strong
association was observed between anti-p140 antibody and rapidly progressive ILD. Anti-p155/140 antibody was
associated with cancer-associated myositis and poor survival.
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Polymyositis (PM) and dermatomyositis (DM) are
systemic autoimmune diseases in which muscles are the
primary target of immune-mediated inflammation. In
addition to muscular inflammation and dysfunction, the
systemic complications of PM and DM involve vessels,
joints, the gastrointestinal tract, cardiac tissues, and lungs
[1]. In particular, damage to lung parenchyma, which
manifests as interstitial lung disease (ILD), and accompa-
nying malignancies are the major prognostic factors that
contribute to mortality in PM and DM patients [2,3]. On
the other hand, amyopathic dermatomyositis (ADM) is a
condition in which the typical skin manifestations of DM
develop without muscle involvement, and it constitutes
the clinical spectrum of inflammatory myositis together
with PM and DM [4]. Clinically amyopathic dermato-
myositis (CADM) is an extended concept of ADM in
which no muscle weakness is observed with or without
subclinical evidence of muscle inflammation on labora-
tory, electrophysiological, and/or radiographic evalua-
tions [5]. Treatment-resistant rapidly progressive
interstitial lung disease (ILD) has been reported to cluster
in ADM/CADM patients [5-7], and appreciable clinical
significance has been conferred upon ADM and/or
CADM (ADM/CADM).
As in other connective tissue diseases, PM and
DM are characterized by autoantibodies to various
cellular components. Some of these autoantibodies are
found specifically in PM and DM patients (referred to
as myositis-specific autoantibodies, MSAs) or in myositis
overlap syndrome patients (myositis-associated autoanti-
bodies, MAAs). The MSAs tend to be mutually exclu-
sive and are associated with certain clinical subsets [8],
which renders MSAs as useful tools to classify clinical
subgroups. The most striking association found to date
concerns the association between anti-aminoacyl-tRNA
synthetase (anti-ARS) antibodies and the presence of
ILD [2]. In recent years, novel autoantibodies have been
identified in inflammatory myositis, such as, anti-
140-kDa polypeptide (anti-p140) [9] and anti-155/
140-kDa polypeptide (anti-p155/140) antibodies [10,11].
Because these antibodies have yet to be extensively stu-
died in non-myositis populations to assure their specifi-
city for myositis and because the presence of anti-p140
antibodies has been largely limited to CADM patients
who do not have clinical muscle symptoms [9,12,13], it
may be currently inappropriate to classify anti-p140 and
anti-p155/140 antibodies as MSAs. However, associa-
tions between these novel antibodies and distinctive
clinical subsets have been found in adult inflammatory
myositis patients; associations between anti-p140 anti-
body and CADM-associated ILD [9,12,13] and between
anti-p155/140 antibody and cancer-associated myositis
are such examples [10-12,14-16]. The clinical usefulness
of these autoantibodies has well been recognized as
diagnostic markers that could potentially alter disease
outcomes by facilitating early diagnosis and treatment.
However, clinical implications regarding these novel
antibodies in adult PM and DM patients have been
limited to a few ethnic cohorts [9-16]. Given that the
phenotypes and severities of connective tissue diseases
are often influenced by genetic background [17,18],
extended observations of other racial groups are manda-
tory. In the present study, we investigated the panel of
defined autoantibodies including MSAs, MAAs, anti-
p140, and anti-p155/140 antibodies in the sera of
Korean inflammatory myositis patients with the inten-
tion to classify clinical subsets of these patients based
on the presence of myositis autoantibodies and to refine
the relationships between these antibodies and disease
manifestations.
Methods
Patients and sera
Forty nine serum samples (n = 11 for PM, n = 38 for
DM) were available from seventy-five patients (n = 20
for PM, n = 55 for DM) consecutively diagnosed as hav-
ing definite inflammatory myositis according to the
Bohan and Peter criteria [19] from March 1993 to
November 2007 at the Rheumatology Clinic of Seoul
National University Hospital. The remaining twenty-six
sera had been examined for the presence of certain
MSAs in our previous study [20], but were not available
for the current study. DM was classified when helio-
trope rash, Gottron’s sign, and/or Gottron’s papule were
present. Patients with myositis overlap syndrome met
both the above criteria and the criteria for another
defined connective tissue disease. Patients with juvenile
DM (age ≤ 18), ADM/CADM (classified according to
the criteria by Sontheimer [5]), or inclusion body myosi-
tis (diagnosed by the presence of typical inclusions on a
stained muscle biopsy under the light microscopy) were
not included.
Clinical information regarding disease manifestations,
laboratory data, radiographic data, and the presence of
internal malignancies was obtained by medical chart
review. Chest radiography (CXR) and/or high resolution
computed tomography (HRCT) were performed at base-
line and repeated every 12 months or when they had
new onset respiratory symptoms. Patients were diag-
nosed as having ILD based on the radiographic evidence
in CXR and/or HRCT findings. Rapidly progressive ILD
was defined to be present when ILD showed radio-
graphic deterioration causing hypoxia within one month
from respiratory symptom onset. All patients underwent
cancer screening, including chest radiography, computed
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stomach and colon. Breast and gynecologic examina-
tions were done for female patients. Patients negative at
initial cancer screening were re-examined whenever
suspected for malignancy during follow-up. Cancer-
associated myositis was identified when cancer was
detected within 3 years of myositis diagnosis [14]. This
study was approved by the Institutional Review Board of
Seoul National University Hospital (#1002-003-308) and
informed consent was obtained from study participants.
Immunoprecipitation assay
Immunoprecipitation was performed using extracts of
HeLa cells, as previously described [13,21]. For RNA
analysis, 2 mg of protein A-Sepharose CL (GE Health-
care, Sweden) incubated with 10 μlo fs e r ai n5 0 0μl
immunoprecipitation buffer (IPP; 10 mM Tris-Cl, 500
mM NaCl, 0.1% Nonidet P-40, pH 8.0) was washed 4
times with 500 μl IPP, resuspended in 400 μlN E T - 2
buffer (50 mM Tris-HCl at pH 7.5, 150 mM NaCl,
0.05% NP-40) and mixed with 100 μl of HeLa cell
extracts (6 × 10
6 cell equivalent per sample) for 2 hrs at
4°C. The Sepharose was then collected, washed 4 times
with NET-2 buffer, and then resuspended in 300 μlo f
NET-2 buffer. To extract bound RNA, 30 μlo f3 . 0M
sodium acetate, 30 μl of 10% sodium dodecyl sulfate
(SDS), 2 μl of carrier yeast tRNA (10 mg/mL; Sigma, St.
Louis, USA) and 300 μl of phenol:chloroform:isoamyl
alcohol (50:50:1, containing 0.1% 8-hydroxyquinolone)
were added. After ethanol precipitation, RNAs were
resolved in 7 M urea-10% polyacrylamide gel, which was
subsequently silver-stained (Bio-Rad, Hercules, USA).
MSA and MAA reactivities was assessed using reference
sera containing autoantibodies to histidyl tRNA synthe-
tase (Jo-1), glycyl tRNA synthetase (EJ), asparaginyl
tRNA synthetase (KS), isoleucyl tRNA synthetase (OJ),
threonyl tRNA synthetase (PL-7), alanyl tRNA synthe-
tase (PL-12), signal recognition particle (SRP), U1 RNP,
Ro, La, Ku, Sm, or Th/To.
For polypeptide analysis, 2 mg of IgG-coated protein
A-Sepharose CL in 400 μl IPP was mixed with 100 μlo f
radiolabeled HeLa cell extract for 2 hrs at 4°C. After 4
washes with IPP, the beads were spun down, boiled for
5 min in 30 μl of sample buffer, and then fractionated
by 10% SDS-polyacrylamide gel electrophoresis. After
autoradiography, autoantibody reactivity was assessed
versus three reference sera, containing anti-p140, anti-
p155/140, or anti-Mi2 antibodies. The presence of anti-
p140 or anti-p155/140 antibodies was defined when
apparent protein precipitates were found either at 140-
kDa (anti-p140) or at 155/140-kDa (anti-p155/140)
which match the reference sera. Studies to further con-
firm the specificities of these antibodies were not
performed.
Statistical analysis
Continuous values are represented as means ± standard
deviation (SD). Statistical analysis was performed using
the Mann Whitney U test and the chi-square test (or
Fisher’s exact test if appropriate) to compare continuous
and categorical variables, respectively. Cumulative survi-
val rates were determined using the Kaplan-Meier
method and the log-rank test; survival times were pre-
sented as means ± standard error (SE). SPSS (SPSS Inc.,
Chicago, IL) was used throughout, and two-sided
p-values of < 0.05 were considered statistically significant.
Results
Clinical characteristics of the study subjects
The study subjects showed a slight female predomi-
nance (61.2% among all study subjects) with a mean age
of 45.4 ± 14.6 (mean ± SD) years (table 1). Patients
were followed for 59.1 ± 51.9 months after the diagnosis
of inflammatory myositis. ILD rates were 18.2% (2/11)
in the PM group and 31.6% (12/38) in the DM group.
All rapidly progressive ILD developed in DM patients
(n = 4). Cancer was present in 12 patients, 11 of whom
were classified as cancer-associated myositis (table 2).
There were 3 myositis overlap cases (n = 1 for DM/
systemic sclerosis, n = 1 for DM/systemic lupus erythe-
matosus (SLE), n = 1 for PM/SLE). Ten patients died
d u r i n gf o l l o w - u po f1 4 . 6±1 9 . 5m o n t h s ;6d i e do fc a n -
cer, 3 of ILD, 1 of bacterial pneumonia, which suggests
that cancer and ILD are the two most important prog-
nostic factors of myositis. Overall, no significant clinical
difference was observed between the PM and DM
groups.
Table 1 Demographic and clinical data of PM and DM
patients
PM
(n = 11)
DM
(n = 38)
Total
(n = 49)
Age at diagnosis (years)† 51.1 ± 15.8 43.7 ± 13.9 45.4 ± 14.6
Gender (F:M) 7:4 23:15 30:19
Disease duration (months)† 44.2 ± 46.9 62.9 ± 53.0 59.1 ± 51.9
Clinical manifestation, n (%)
Fever 3 (27.3) 11 (28.9) 14 (28.6)
Raynaud’s phenomenon 2 (18.2) 6 (15.8) 8 (16.3)
Arthralgia 2 (18.2) 14 (36.8) 16 (32.7)
Dysphagia 0 (0) 9 (23.7) 9 (18.4)
Cardiac involvement 2 (18.2) 0 (0) 2 (4.1)
ILD 2 (18.2) 12 (31.6) 14 (28.6)
Malignancy 3 (27.3) 9 (23.7) 12 (24.5)
Myositis overlap 1 (9.1) 2 (5.3) 3 (6.1)
† mean ± SD.
DM = dermatomyositis, F = female, ILD = interstitial lung disease, M = male,
PM = polymyositis.
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Immunoprecipitation assays showed that 9 patients had
anti-p140 (18.4%), 8 anti-p155/140 (16.3%), 7 anti-Mi2
(14.3%), 6 anti-ARS (12.2%), and 1 anti-SRP (2.0%) anti-
bodies, and that 10 patients had MAAs (figure 1 and
table 3). The MSAs, anti-p140, and anti-p155/140 anti-
bodies were found to be mutually exclusive. Anti-p140,
anti-p155/140, and anti-Mi2 were exclusively found in
DM patients at the prevalence of 23.7% (9/38), 21.1%
(8/38), and 18.4% (7/38), respectively. Anti-ARS antibo-
dies included anti-Jo-1 (n = 3), anti-PL-7 (n = 1), anti-
PL-12 (n = 1), and anti-EJ (n = 1) antibodies. Of the
MAAs, anti-U1RNP antibody was most frequently
observed (6/49, 12.2%). Anti-Ku, anti-Sm, and anti-Th/
To antibodies were not detected. Three cases had auto-
antibodies with unknown specificities.
Associations between autoantibodies and clinical subsets
We then examined whether any associations existed
between the myositis autoantibodies and the clinical fea-
tures of myositis. Table 4 presents the clinical character-
istics of 9 patients positive for anti-p140 antibody and
Table 2 Clinical data of 12 patients who had malignancy
Malignancy (n = 12)
Age
(years)
Sex Diagnosis ILD Time of
detection†
(months)
Primary
site
Cancer-associated
myositis
Detected
autoantibodies
1 56 F DM - -11 Esophagus Yes Anti-p155/140
2 46 F DM - +18 Breast Yes Anti-Mi2
3 59 M DM - -1 Stomach Yes Anti-p155/140
4 53 F DM - 0 Lung Yes Anti-p155/140
5 74 F PM/SLE + - 48 Stomach No Anti-PL-7
6 57 M PM - 0 Liver Yes none
7 36 F DM/SLE + -1 Thyroid Yes Anti-PL-12
8 36 M DM - 0 Lymphoma Yes Anti-p155/140
9 50 F DM - -2 Breast Yes Anti-p155/140
10 61 M DM + +22 Lymphoma Yes Anti-Jo-1
11 68 M DM - +2 Lung Yes none
12 65 M PM + 0 Stomach Yes Anti-Jo-1
†Relative to time of myositis diagnosis.
DM = dermatomyositis, F = female, ILD = interstitial lung disease, M = male, PM = polymyositis, SLE = systemic lupus erythematosus.
Figure 1 Representative immunoprecipitation results. A. tRNA precipitated by patient and prototype sera. Patients 1 - 3 were positive for
anti-Jo-1 antibody, patient 4 for anti-PL-12 antibody, patient 5 for anti-EJ antibody, and patient 6 for anti-PL-7 antibody. B. Polypeptides
precipitated by patient and prototype sera. Patients B, F, I, and J were positive for anti-p140 antibody, patients C and E for anti-p155/140
antibody, patients A and H for anti-Mi2 antibody, and patient G (= patient 4) for anti-PL-12 antibody.
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with anti-ARS, anti-p140, or anti-p155/140 antibodies.
Anti-ARS positive patients had a higher frequency of
ILD than negative patients (5/6 vs. 9/43, p = 0.005),
with a 100% prevalence of ILD in anti-Jo-1 positive
patients. One PM patient with anti-PL-7 antibody did
not develop ILD but had serositis. Three of 6 anti-ARS
positive patients had cancer-associated myositis without
statistically significant association (3/6 vs. 8/43,
p = 0.117). The clinical phenotype of ILD in the pre-
sence of anti-ARS antibody was either slowly progressive
or stable. Anti-p140 positive patients also showed a
higher frequency of ILD than anti-p140 negative
patients (6/9 vs. 8/40, p = 0.011). In particular, rapidly
progressive ILD was found to be exclusively associated
with the anti-p140 antibody (4/9 vs. 0/40, p = 0.001).
The mean survival time (mean ± SE) of patients with
rapidly progressive ILD (n = 4) was 10.2 ± 5.8 months,
whereas that of those without ILD (n = 45) was 109.6 ±
9.5 months (p = 0.002), which suggest that rapidly pro-
gressive ILD is a major prognostic factor. Anti-p155/
140 antibody was found to be associated with cancer-
associated myositis (5/8 vs. 6/41, p = 0.009). Anti-p155/
140 positive cancer patients (n = 5) tended to have poor
outcome, showing a shorter survival time than anti-
p155/140 negative cancer patients (n = 6) (19.2 ± 7.6 vs.
72.7 ± 17.0 months, p = 0.052); this difference was sig-
nificant when the analysis was confined to DM patients
(19.2 ± 7.6 vs. 65.0 ± 3.5 months, p = 0.032) (figure 2).
No evidence of necrotizing myositis or cardiac involve-
ment was observed in one patient with anti-SRP anti-
body. MAAs were not found to be associated with any
particular clinical features of myositis.
Discussion
The present study shows that anti-p140 (18.4%), anti-
p155/140 (16.3%), anti-Mi2 (14.3%), and anti-ARS
(12.2%) antibodies are common autoantibodies in Kor-
ean patients with inflammatory myositis; the common
prevalence of anti-ARS and anti-Mi2 antibodies is
consistent with our previous result [20]. Anti-p140, anti-
p155/140, and anti-Mi2 antibodies were found exclu-
sively in DM patients as previously reported [9-16], and
the first two antibodies were found to be associated
with distinctive clinical subsets of myositis; anti-p140
antibody with rapidly progressive ILD and anti-p155/140
antibody with cancer-associated myositis. Furthermore,
anti-p155/140 antibody was found to be associated with
poor survival in cancer-associated DM patients. Anti-
ARS antibody was present in both PM and DM patients
and found to be associated with stable or slowly pro-
gressive ILD.
The most distinguished findings of this study are the
high prevalence of anti-p140 antibody in classic DM
patients and the association of this antibody with rapidly
progressive ILD independent of CADM. Myositis-asso-
ciated rapidly progressive ILD has been reported in both
classic DM and ADM/CADM patients [5-7,22-25].
Although rapidly progressive ILD often occurs in
patients with ADM/CADM [5-7], its true incidence
remains unknown due to poor estimates of the propor-
tions of ADM/CADM patients in populations. Previous
Japanese studies have reported that anti-p140 antibody
is mainly found in CADM rather than classic DM
patients [9,12,13], but these studies enrolled few classic
DM patients with rapidly progressive ILD to conclu-
sively determine whether anti-p140 antibody is a risk
Table 3 Antibody profiles determined by
immunoprecipitation
PM
n = 11 (%)
DM
n = 38 (%)
Total
n = 49 (%)
Myositis specific antibodies 4 (36.4) 10 (26.3) 14 (28.6)
Anti-ARS antibodies 3 (27.3) 3 (7.9) 6 (12.2)
Anti-Mi2 antibody 0 7 (18.4) 7 (14.3)
Anti-SRP antibody 1 (9.1) 0 1 (2.0)
Anti-p140 antibody 0 9 (23.7) 9 (18.4)
Anti-p155/140 antibody 0 8 (21.1) 8 (16.3)
Myositis associated antibodies 1 (9.1) 9 (23.7) 10 (20.4)
Anti-U1 RNP 0 6 (15.8) 6 (12.2)
Anti-Ro 1 (9.0) 3 (7.9) 4 (8.2)
Anti-La 0 1 (2.6) 1 (2.0)
ARS = aminoacyl tRNA synthetase, DM = dermatomyositis, PM = polymyositis,
SRP = signal recognition particle, RNP = ribonucleoprotein.
Table 4 Clinical characteristics of 9 patients positive for
anti-p140 antibody
12345 6 7 8 9
Age at myositis
diagnosis
48 67 18 46 55 21 53 51 53
Sex F F M M F F F M M
Diagnosis DM DM DM DM DM DM DM DM DM
Interstitial lung
disease
++-++ - - + +
Rapidly
progressive
type
No Yes No Yes Yes Yes
Muscle weakness +++++ + + + +
Creatine kinase† 31 20 486 212 930 19487 775 1273 140
Lactate
dehydrogenase†
280 407 765 493 437 6916 748 295 249
Abnormal
electromyography
+++++ + + + +
Biopsy proven
myositis
+++++ + + + +
†Normal range; 20-270 IU/mL for creatine kinase and 100-225 IU/mL for
lactate dehydrogenase.
DM = dermatomyositis, F = female, M = male
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Sato et al reported that the RNA helicase encoded by
melanoma differentiation-associated gene 5 (MDA5) is
an autoantigen recognized by anti-p140 antibody (which
currently is called “anti-CADM-140 antibody”), and
went on to develop an enzyme-linked immunosorbent
assay technique using the recombinant protein [26].
According to their results, anti-p140 antibody is exclu-
sively found in CADM patients with or without rapidly
progressive ILD; no significant difference was found
between the antibody titers of those with and without
ILD. This finding suggests that anti-p140 antibody is
primarily associated with the CADM phenotype than
rapidly progressive ILD in Japanese patients. On the
other hand, our study shows that anti-p140 antibody is
one of the most common myositis autoantibodies in
Korean patients with classic DM, and that it has a strik-
ing association with rapidly progressive ILD. Because no
patient in the present study met the ADM/CADM cri-
teria [5], these observations suggest that anti-p140 anti-
body is primarily associated with rapidly progressive
ILD independently of CADM at least in Korean patients.
It has been reported that anti-p155 and/or anti-p155/
140 antibodies are associated with cancer-associated
myositis [10-12,14-16], and our results support this
contention. In addition, we were able to confirm the
previously reported lower incidence of ILD among anti-
p155/140 positive patients [10-12,14,15]. The poor can-
cer-related outcome of anti-p155/140 positive patients
compared with anti-p155/140 negative patients is a
novel finding. However, our study is adopting a small
number of patients to conclude with a certainty. We are
cautious to claim the prognostic value of this antibody
in cancer-associated myositis until it is proven via multi-
variate analyses that appropriately adjust other prognos-
tic factors. Further studies employing a larger number
of cancer-associated myositis patients are warranted to
confirm this result and to determine if anti-p155/140
antibody predates or follows the onset of cancer, if its
titer correlates with cancer progression, or if certain
types of cancers are more prone to develop anti-p155/
140 antibody. Another interesting finding was that 3 out
of 6 anti-ARS positive patients had cancer-associated
myositis, which, however, was not statistically signifi-
cant. In fact, cancer-associated myositis in the presence
of other myositis autoantibodies than anti-p155/140
antibodies (such as anti-ARS or anti-Mi2) has been pre-
viously reported [14,27,28]. Although anti-p140 positive
patients have been shown to have low prevalence of
malignancy [9,12], the presence of other myositis auto-
antibodies rather than anti-p155/140 antibodies does
not seem to rule out the presence of cancer in inflam-
matory myositis patients.
The limitations of this study are as follows. First, 26
sera were dropped out during consecutive enrollment,
which leaves the possibility of selection bias. However,
the clinical implications of anti-p140 and anti-p155/140
antibodies observed in this study are unlikely to be
affected, because there was only one patient with rapidly
progressive ILD and none with malignancy among these
26 patients during 78 ± 59.9 months of follow-up (data
not shown). Second, we did not further examine the
specificities of myositis autoantibodies beyond immuno-
precipitation. Therefore, anti-p140 and anti-p155/140
Table 5 Associations between myositis autoantibodies and clinical subsets
Anti-ARS Anti-p140 Anti-p155/140 Anti-Mi2 Total
n=6 n=9 n=8 n=7 n=4 9
ILD 5 6 0 0 14
Rapidly progressive ILD 0 4 4
Cancer-associated myositis 3 0 5 1 11
Mortality 2 3 4 0 10
ILD-related 0 3 0 0 3
Cancer-related 1 0 4 0 6
ARS = aminoacyl tRNA synthetase; ILD = interstitial lung disease.
Figure 2 Cumulative survival rates in cancer-associated
dermatomyositis patients according to anti-p155/140 antibody
status.
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represent anti-CADM-140 and anti-p155/140 antibodies
that have previously been shown to recognize MDA5
[13,26] and transcriptional intermediary factor 1-g [29],
respectively. However, high accuracy of immunoprecipi-
tation to specifically detect anti-p140 or anti-p155/140
antibodies in inflammatory myositis patients has been
previously reported [30]. In addition, distinctive clinical
features have been demonstrated in association with
each myositis autoantibody defined by immunoprecipita-
tion in our study, which is generally in parallel with the
results of previous studies [9-16].
Conclusions
In summary, anti-p140 and anti-p155/140 antibodies
were commonly found autoantibodies in Korean patients
with inflammatory myositis. Despite the lack of CADM
patients in the study subjects, a strong association was
observed between anti-p140 antibody and rapidly pro-
gressive ILD. Anti-p155/140 antibody was associated
with cancer-associated myositis and poor survival, which
should be confirmed in a study of larger scale.
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